On top of that, an analyst cut his price target on the Denmark-based pharmaceutical company. Novo Nordisk (NYSE: NVO) stock ...

Medically reviewed by Kristie Reed, PharmD Semaglutide is a medication mainly used to lower blood sugar levels in people with type 2 diabetes. However, it may also help manage weight due to its ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

Hims and Hers stock rally looms with bullish EMAs, Novo Nordisk partnership, ZAVA acquisition, and new product launches ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

McDonald’s faces falling visits and shrinking demand as GLP-1 drugs and price fatigue reshape consumer habits.

Pennsylvania Governor Josh Shapiro's office has said it is looking to change eligibility for weight loss drugs as part of its 2025-26 budget plans.

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the summary of a small study that suggests the company has another foothol ...